88 results
Page 2 of 5
8-K
s7f0pry18vgqb7 og
4 Oct 23
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
6:56am
424B3
g2o5ks
28 Aug 23
Prospectus supplement
9:10am
S-4/A
dby1v6kg3p1xqvyee1
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4/A
EX-10.46
5gd6gjb qrjiby7
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
8-K
EX-99.1
6pcny7j4j9 nby1
9 Aug 23
Immunome Reports Second Quarter 2023 Financial Results
8:27am
S-4
40wd 7rybw3xg
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-99.1
c3batkfrck 0wj5zxdhq
5 Jul 23
Business combination disclosure
5:15pm
8-K
EX-99.1
jz0dkd2tfw qm4ijk1q
5 Jul 23
Morphimmune and Immunome Combined Corporate Presentation July 2023
5:12pm
425
EX-99.2
xow tkg98e791o9aw
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-99.2
adgolh6w
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
8-K
EX-99.1
435 4r0b63
5 May 23
Immunome Reports First Quarter 2023 Financial Results
8:19am
PRE 14A
oivsl
7 Apr 23
Preliminary proxy
6:29am
8-K
EX-99.1
f0nwbs4x9npxa
15 Nov 22
Other Events
4:17pm
8-K
EX-99.1
ockbq1w
14 Nov 22
Immunome Reports Third Quarter 2022 Financial Results
9:06am
8-K
EX-99.1
tyxvw2ihmd0
5 Aug 22
Immunome Reports Second Quarter 2022 Financial Results
8:15am